9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares.